Download PDF
CC BY-NC-ND 4.0 · Thromb Haemost 2022; 122(09): 1486-1501
DOI: 10.1055/a-1825-2915
Cellular Haemostasis and Platelets

Enrichment of Complement, Immunoglobulins, and Autoantibody Targets in the Proteome of Platelets from Patients with Systemic Lupus Erythematosus

Carl Petrus Linge 
1   Section of Rheumatology, Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Lund, Skåne, Sweden
,
Andreas Jern
1   Section of Rheumatology, Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Lund, Skåne, Sweden
,
Helena Tydén
1   Section of Rheumatology, Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Lund, Skåne, Sweden
,
Birgitta Gullstrand
1   Section of Rheumatology, Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Lund, Skåne, Sweden
,
Hong Yan
2   Swedish National Infrastructure for Biological Mass Spectrometry, BioMS, Lund, Sweden
,
Charlotte Welinder
3   Section of Oncology, Clinical Sciences, Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Lund, Skåne, Sweden
,
Robin Kahn
4   Section of Pediatrics, Department of Clinical Sciences Lund, Wallenberg Center for Molecular Medicine, Lund University, Lund, Skåne, Sweden
,
Andreas Jönsen
1   Section of Rheumatology, Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Lund, Skåne, Sweden
,
John W. Semple
5   Division of Hematology and Transfusion Medicine, Lund University, Lund, Sweden
6   Clinical Immunology and Transfusion Medicine, Office of Medical Services, Region Skåne, Lund, Sweden
7   Department of Pharmacology, University of Toronto, Toronto, Canada
,
Anders A. Bengtsson
1   Section of Rheumatology, Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Lund, Skåne, Sweden
› Author Affiliations Funding This work was supported by grants from the Ulla and Roland Gustafsson foundation, Thelma Zoega Foundation for Medical Research, the Royal Physiographic Society of Lund, the Swedish Research Council (2018–02516), King Gustaf V's 80th Birthday Foundation, Alfred Österlund's Foundation, the Anna-Greta Crafoord Foundation, Greta and Johan Kock's Foundation, Skåne University Hospital, the Swedish Rheumatism Association, and the Medical Faculty of Lund University.
› Further Information
   Permissions and Reprints


Abstract

Background Systemic lupus erythematosus (SLE) is a complex disease characterized by autoimmunity toward apoptotic cells, excessive amounts of circulating immune complexes, and complement activation. A decreased platelet size has been observed in SLE and their nonhemostatic functions may play an active role in the disease. The main objective of this study was to find clues that could explain their decreased size and functional role, analyzing the entire platelet proteome.

Methods Platelets were isolated from 23 patients with SLE. The five individuals with the highest and lowest average platelet forward scatter were selected for further analysis. Platelet protein content was analyzed using liquid chromatography with tandem mass spectrometry (LC-MS/MS) and compared with platelets from five healthy controls. Data are available via ProteomeXchange with identifier PXD031202.

Results Out of 2,572 proteins identified, 396 had significantly different levels (ANOVA q-value ≤ 0.01). Forty proteins, including immunoglobulin-, complement- and phosphatidylserine-binding proteins had higher abundance in platelets from SLE patients, largely independent of size (fold difference of ≥1.5 and a t-test p-value of ≤0.05 as cut-off). Functional characterization revealed increased degranulation and skewed hemostatic balance in platelets from SLE patients. In the SLE proteome, immunoglobulin proteins were negatively correlated to serum complement C3 and C4 and the highest relative levels were detected in platelets of normal size.

Conclusion Platelets from SLE patients shared a specific protein profile, including immunoglobulins, complement proteins, and autoantigens, largely independent of the platelet size and in agreement with an integrated role for platelets in SLE.

Keywords

SLE - immunoglobulins - complement - autoantibodies - platelet

Supplementary Material

Supplementary Material



Publication History

Received: 14 September 2021

Accepted: 09 March 2022

Accepted Manuscript online:
13 April 2022

Article published online:
24 July 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Linge P, Fortin PR, Lood C, Bengtsson AA, Boilard E. The non-haemostatic role of platelets in systemic lupus erythematosus. Nat Rev Rheumatol 2018; 14 (04) 195-213
    CrossrefPubMedGoogle Scholar
  • 2 Maouia A, Rebetz J, Kapur R, Semple JW. The immune nature of platelets revisited. Transfus Med Rev 2020; 34 (04) 209-220
    CrossrefPubMedGoogle Scholar
  • 3 Scherlinger M, Guillotin V, Douchet I. et al. Selectins impair regulatory T cell function and contribute to systemic lupus erythematosus pathogenesis. Sci Transl Med 2021; 13 (600) eabi4994
    CrossrefPubMedGoogle Scholar
  • 4 Peerschke EI, Yin W, Grigg SE, Ghebrehiwet B. Blood platelets activate the classical pathway of human complement. J Thromb Haemost 2006; 4 (09) 2035-2042
    CrossrefPubMedGoogle Scholar
  • 5 Pretorius E, du Plooy J, Soma P, Gasparyan AY. An ultrastructural analysis of platelets, erythrocytes, white blood cells, and fibrin network in systemic lupus erythematosus. Rheumatol Int 2014; 34 (07) 1005-1009
    CrossrefPubMedGoogle Scholar
  • 6 Nhek S, Clancy R, Lee KA. et al. Activated platelets induce endothelial cell activation via an interleukin-1β pathway in systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 2017; 37 (04) 707-716
    CrossrefPubMedGoogle Scholar
  • 7 Becker Y, Loignon RC, Julien AS. et al. Anti-mitochondrial autoantibodies in systemic lupus erythematosus and their association with disease manifestations. Sci Rep 2019; 9 (01) 4530
    CrossrefPubMedGoogle Scholar
  • 8 Lood C, Tydén H, Gullstrand B. et al. Decreased platelet size is associated with platelet activation and anti-phospholipid syndrome in systemic lupus erythematosus. Rheumatology (Oxford) 2017; 56 (03) 408-416
    PubMedGoogle Scholar
  • 9 Hartmann LT, Alegretti AP, Machado ABMP. et al. Assessment of mean platelet volume in patients with systemic lupus erythematosus. Open Rheumatol J 2018; 12: 129-138
    CrossrefPubMedGoogle Scholar
  • 10 Delgado-García G, Galarza-Delgado DA, Colunga-Pedraza I. et al. Mean platelet volume is decreased in adults with active lupus disease. Rev Bras Reumatol 2016; 56 (06) 504-508
    PubMedGoogle Scholar
  • 11 Zhao CN, Mao YM, Wang P. et al. Lack of association between mean platelet volume and disease activity in systemic lupus erythematosus patients: a systematic review and meta-analysis. Rheumatol Int 2018; 38 (09) 1635-1641
    CrossrefPubMedGoogle Scholar
  • 12 Wirestam L, Gullstrand B, Jern A. et al. Low intra-individual variation in mean platelet volume over time in systemic lupus erythematosus. Front Med (Lausanne) 2021; 8: 638750
    CrossrefPubMedGoogle Scholar
  • 13 Cloutier N, Allaeys I, Marcoux G. et al. Platelets release pathogenic serotonin and return to circulation after immune complex-mediated sequestration. Proc Natl Acad Sci U S A 2018; 115 (07) E1550-E1559
    CrossrefPubMedGoogle Scholar
  • 14 Lood C, Tydén H, Gullstrand B. et al. Type I interferon-mediated skewing of the serotonin synthesis is associated with severe disease in systemic lupus erythematosus. PLoS One 2015; 10 (04) e0125109
    CrossrefPubMedGoogle Scholar
  • 15 McArthur K, Chappaz S, Kile BT. Apoptosis in megakaryocytes and platelets: the life and death of a lineage. Blood 2018; 131 (06) 605-610
    CrossrefPubMedGoogle Scholar
  • 16 Leytin V. Apoptosis in the anucleate platelet. Blood Rev 2012; 26 (02) 51-63
    CrossrefPubMedGoogle Scholar
  • 17 Leader A, Pereg D, Lishner M. Are platelet volume indices of clinical use? A multidisciplinary review. Ann Med 2012; 44 (08) 805-816
    CrossrefPubMedGoogle Scholar
  • 18 Pieterse E, van der Vlag J. Breaking immunological tolerance in systemic lupus erythematosus. Front Immunol 2014; 5: 164
    CrossrefPubMedGoogle Scholar
  • 19 Dieker J, Tel J, Pieterse E. et al. Circulating apoptotic microparticles in systemic lupus erythematosus patients drive the activation of dendritic cell subsets and prime neutrophils for NETosis. Arthritis Rheumatol 2016; 68 (02) 462-472
    CrossrefPubMedGoogle Scholar
  • 20 Perez-Riverol Y, Bai J, Bandla C. et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res 2022; 50 (D1): D543-D552
    CrossrefPubMedGoogle Scholar
  • 21 Handtke S, Thiele T. Large and small platelets-(When) do they differ?. J Thromb Haemost 2020; 18 (06) 1256-1267
    CrossrefPubMedGoogle Scholar
  • 22 Franceschini A, Szklarczyk D, Frankild S. et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 2013; 41 (Database issue): D808-D815
    CrossrefPubMedGoogle Scholar
  • 23 Rau JC, Beaulieu LM, Huntington JA, Church FC. Serpins in thrombosis, hemostasis and fibrinolysis. J Thromb Haemost 2007; 5 (Suppl. 01) 102-115
    CrossrefPubMedGoogle Scholar
  • 24 Schattner M. Platelets and galectins. Ann Transl Med 2014; 2 (09) 85
    PubMedGoogle Scholar
  • 25 Pacienza N, Pozner RG, Bianco GA. et al. The immunoregulatory glycan-binding protein galectin-1 triggers human platelet activation. FASEB J 2008; 22 (04) 1113-1123
    CrossrefPubMedGoogle Scholar
  • 26 Scott K, Weinberg C. Galectin-1: a bifunctional regulator of cellular proliferation. Glycoconj J 2002; 19 (7–9): 467-477
    CrossrefPubMedGoogle Scholar
  • 27 George JN, Saucerman S, Levine SP, Knieriem LK, Bainton DF. Immunoglobulin G is a platelet alpha granule-secreted protein. J Clin Invest 1985; 76 (05) 2020-2025
    CrossrefPubMedGoogle Scholar
  • 28 Miyakis S, Giannakopoulos B, Krilis SA. Beta 2 glycoprotein I–function in health and disease. Thromb Res 2004; 114 (5–6): 335-346
    CrossrefPubMedGoogle Scholar
  • 29 McDonnell T, Wincup C, Buchholz I. et al. The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. Blood Rev 2020; 39: 100610
    CrossrefPubMedGoogle Scholar
  • 30 Mutlu A, Gyulkhandanyan AV, Freedman J, Leytin V. Concurrent and separate inside-out transition of platelet apoptosis and activation markers to the platelet surface. Br J Haematol 2013; 163 (03) 377-384
    CrossrefPubMedGoogle Scholar
  • 31 D'Agnillo P, Levine JS, Subang R, Rauch J. Prothrombin binds to the surface of apoptotic, but not viable, cells and serves as a target of lupus anticoagulant autoantibodies. J Immunol 2003; 170 (06) 3408-3422
    CrossrefPubMedGoogle Scholar
  • 32 Farrah T, Deutsch EW, Omenn GS. et al. A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. Mol Cell Proteomics 2011; 10 (09) 006353
    CrossrefPubMedGoogle Scholar
  • 33 Cuenca-Zamora EJ, Ferrer-Marín F, Rivera J, Teruel-Montoya R. Tubulin in platelets: when the shape matters. Int J Mol Sci 2019; 20 (14) E3484
    CrossrefPubMedGoogle Scholar
  • 34 Clemetson KJ, Clemetson JM, Proudfoot AE, Power CA, Baggiolini M, Wells TN. Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. Blood 2000; 96 (13) 4046-4054
    CrossrefPubMedGoogle Scholar
  • 35 Wirtz TH, Tillmann S, Strüßmann T. et al. Platelet-derived MIF: a novel platelet chemokine with distinct recruitment properties. Atherosclerosis 2015; 239 (01) 1-10
    CrossrefPubMedGoogle Scholar
  • 36 Burkhart JM, Vaudel M, Gambaryan S. et al. The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. Blood 2012; 120 (15) e73-e82
    CrossrefPubMedGoogle Scholar
  • 37 Milioli M, Ibáñez-Vea M, Sidoli S, Palmisano G, Careri M, Larsen MR. Quantitative proteomics analysis of platelet-derived microparticles reveals distinct protein signatures when stimulated by different physiological agonists. J Proteomics 2015; 121: 56-66
    CrossrefPubMedGoogle Scholar
  • 38 Ekdahl KN, Bengtsson AA, Andersson J. et al. Thrombotic disease in systemic lupus erythematosus is associated with a maintained systemic platelet activation. Br J Haematol 2004; 125 (01) 74-78
    CrossrefPubMedGoogle Scholar
  • 39 Lood C, Eriksson S, Gullstrand B. et al. Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus–a possible link to venous thrombosis?. Lupus 2012; 21 (13) 1423-1432
    CrossrefPubMedGoogle Scholar
  • 40 Adelson E, Rheingold JJ, Crosby WH. The platelet as a sponge: a review. Blood 1961; 17: 767-774
    CrossrefPubMedGoogle Scholar
  • 41 Berger G, Massé JM, Cramer EM. Alpha-granule membrane mirrors the platelet plasma membrane and contains the glycoproteins Ib, IX, and V. Blood 1996; 87 (04) 1385-1395
    CrossrefPubMedGoogle Scholar
  • 42 Handtke S, Steil L, Palankar R. et al. Role of platelet size revisited-function and protein composition of large and small platelets. Thromb Haemost 2019; 119 (03) 407-420
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Najaoui A, Bakchoul T, Stoy J. et al. Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP). Eur J Haematol 2012; 88 (02) 167-174
    CrossrefPubMedGoogle Scholar
  • 44 Arman M, Krauel K. Human platelet IgG Fc receptor FcγRIIA in immunity and thrombosis. J Thromb Haemost 2015; 13 (06) 893-908
    CrossrefPubMedGoogle Scholar
  • 45 Huang ZY, Chien P, Indik ZK, Schreiber AD. Human platelet FcγRIIA and phagocytes in immune-complex clearance. Mol Immunol 2011; 48 (04) 691-696
    CrossrefPubMedGoogle Scholar
  • 46 Melki I, Allaeys I, Tessandier N. et al. FcγRIIA expression accelerates nephritis and increases platelet activation in systemic lupus erythematosus. Blood 2020; 136 (25) 2933-2945
    CrossrefPubMedGoogle Scholar
  • 47 Speth C, Rambach G, Würzner R. et al. Complement and platelets: mutual interference in the immune network. Mol Immunol 2015; 67 (01) 108-118
    CrossrefPubMedGoogle Scholar
  • 48 Murata K, Baldwin III WM. Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection. Transplant Rev (Orlando) 2009; 23 (03) 139-150
    CrossrefPubMedGoogle Scholar
  • 49 Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11 (09) 785-797
    CrossrefPubMedGoogle Scholar
  • 50 Macedo AC, Isaac L. Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway. Front Immunol 2016; 7: 55
    CrossrefPubMedGoogle Scholar
  • 51 Kingsmore SF, Thompson JM, Crockard AD. et al. Measurement of circulating immune complexes containing IgG, IgM, IgA and IgE by flow cytometry: correlation with disease activity in patients with systemic lupus erythematosus. J Clin Lab Immunol 1989; 30 (01) 45-52
    PubMedGoogle Scholar
  • 52 Svenungsson E, Gustafsson JT, Grosso G. et al. Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus. Rheumatology (Oxford) 2020; 59 (11) 3264-3274
    CrossrefPubMedGoogle Scholar
  • 53 Truedsson L, Bengtsson AA, Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity 2007; 40 (08) 560-566
    CrossrefPubMedGoogle Scholar
  • 54 Ho YC, Ahuja KDK, Körner H, Adams MJ. β2GP1, anti-β2GP1 antibodies and platelets: key players in the antiphospholipid syndrome. Antibodies (Basel) 2016; 5 (02) E12
    CrossrefPubMedGoogle Scholar
  • 55 Maiti SN, Balasubramanian K, Ramoth JA, Schroit AJ. Beta-2-glycoprotein 1-dependent macrophage uptake of apoptotic cells. Binding to lipoprotein receptor-related protein receptor family members. J Biol Chem 2008; 283 (07) 3761-3766
    CrossrefPubMedGoogle Scholar
  • 56 Janko C, Jeremic I, Biermann M. et al. Cooperative binding of annexin A5 to phosphatidylserine on apoptotic cell membranes. Phys Biol 2013; 10 (06) 065006
    CrossrefPubMedGoogle Scholar
  • 57 Fadok VA, de Cathelineau A, Daleke DL, Henson PM, Bratton DL. Loss of phospholipid asymmetry and surface exposure of phosphatidylserine is required for phagocytosis of apoptotic cells by macrophages and fibroblasts. J Biol Chem 2001; 276 (02) 1071-1077
    CrossrefPubMedGoogle Scholar
  • 58 Martin M, Leffler J, Blom AM. Annexin A2 and A5 serve as new ligands for C1q on apoptotic cells. J Biol Chem 2012; 287 (40) 33733-33744
    CrossrefPubMedGoogle Scholar
  • 59 Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 2004; 34 (02) 501-537
    CrossrefPubMedGoogle Scholar
  • 60 Alessandri C, Conti F, Pendolino M, Mancini R, Valesini G. New autoantigens in the antiphospholipid syndrome. Autoimmun Rev 2011; 10 (10) 609-616
    CrossrefPubMedGoogle Scholar
  • 61 Nicolaou O, Kousios A, Hadjisavvas A, Lauwerys B, Sokratous K, Kyriacou K. Biomarkers of systemic lupus erythematosus identified using mass spectrometry-based proteomics: a systematic review. J Cell Mol Med 2017; 21 (05) 993-1012
    CrossrefPubMedGoogle Scholar
  • 62 Wigren M, Svenungsson E, Mattisson IY. et al. Cardiovascular disease in systemic lupus erythematosus is associated with increased levels of biomarkers reflecting receptor-activated apoptosis. Atherosclerosis 2018; 270: 1-7
    CrossrefPubMedGoogle Scholar
  • 63 Saraste A, Pulkki K. Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res 2000; 45 (03) 528-537
    CrossrefPubMedGoogle Scholar
  • 64 Melki I, Tessandier N, Zufferey A, Boilard E. Platelet microvesicles in health and disease. Platelets 2017; 28 (03) 214-221
    CrossrefPubMedGoogle Scholar
  • 65 Andreoli L, Fredi M, Nalli C, Franceschini F, Meroni PL, Tincani A. Antiphospholipid antibodies mediate autoimmunity against dying cells. Autoimmunity 2013; 46 (05) 302-306
    CrossrefPubMedGoogle Scholar
  • 66 Avriel A, Fleischer S, Friger M. et al. Prediction of antiphospholipid syndrome using annexin a5 competition assay in patients with SLE. Clin Rheumatol 2016; 35 (12) 2933-2938
    CrossrefPubMedGoogle Scholar
  • 67 Sarter K, Janko C, André S. et al. Autoantibodies against galectins are associated with antiphospholipid syndrome in patients with systemic lupus erythematosus. Glycobiology 2013; 23 (01) 12-22
    CrossrefPubMedGoogle Scholar
  • 68 Arandjelovic S, Ravichandran KS. Phagocytosis of apoptotic cells in homeostasis. Nat Immunol 2015; 16 (09) 907-917
    CrossrefPubMedGoogle Scholar
  • 69 Alessandri C, Sorice M, Bombardieri M. et al. Antiphospholipid reactivity against cardiolipin metabolites occurring during endothelial cell apoptosis. Arthritis Res Ther 2006; 8 (06) R180
    CrossrefPubMedGoogle Scholar
  • 70 Bryk AH, Wiśniewski JR. Quantitative analysis of human red blood cell proteome. J Proteome Res 2017; 16 (08) 2752-2761
    CrossrefPubMedGoogle Scholar